Evaluation of the dofetilide risk-management program

American Heart Journal

Volumn 146, Issue 5, 2003, Pages 894-901

  Allen LaPointe, Nancy M ^a   Chen, Anita ^a   Hammill, Bradley ^a   DeLong, Elizabeth ^a   Kramer, Judith M ^a   Califf, Robert M ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAPACE AF; DOFETILIDE; SOTALOL;

ADULT; AGED; COMPLETE HEART BLOCK; CREATININE BLOOD LEVEL; DIARRHEA; DRUG LABELING; DYSPNEA; ELECTROCARDIOGRAM; FEMALE; HEALTH PROGRAM; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; HYPOTENSION; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; RISK MANAGEMENT; SINUS BRADYCARDIA; SKIN TINGLING; TORSADE DES POINTES;

EID: 0242636418     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(03)00409-5     Document Type: Article

References (10)

1. Dofetilide. Physicians' desk reference. Montvale (NJ): Medical Economics Company; 2002. p. 2717-22.
2. Wang T, Bergstrand RH, Thompson KA. Concentration-dependent pharmacologic properties of sotalol. Am J Cardiol 1986;57:1160-5.
3. Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design and patient characteristics of the DIAMOND studies: Danish Investigations of Arrhythmia and Mortality on Dofetilide. Clin Cardiol 1997;20:704-10.
4. Le Coz F, Funck-Brentano C, Morell T. Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization. Clin Pharmacol Ther 1995;57:533-42.
5. Singh S, Zoble RG, Yellen L. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000;102:2385-90.
6. Torp-Pedersen C, Moller M, Bloch-Thomsen PE. Dofetilide in patients with congestive heart failure and left ventricular dysfunction: Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999;341:857-65.
7. Ahnve S. Correction of the QT interval for heart rate: review of different formulas and the use of Bazett's formula in myocardial infarction. Am Heart J 1985;109:568-74.
8. Funck-Brentano C, Jaillon P. Rate-corrected QT interval: techniques and limitations. Am J Cardiol 1993;72:17-22B.
9. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
10. Allen LaPointe NM, Kramer JM, Weinfurt KP. Practitioner acceptance of the dofetilide risk-management program. Pharmacotherapy 2002;22:1041-6.